Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ALDX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Reproxalap Ophthalmic Solution (0.1%) | Allergic Conjunctivitis | Phase 3 · NCT05234554 | Completed |
| Reproxalap Ophthalmic Solution (0.25%) QID | Dry Eye | Phase 3 · NCT03879863 | Completed |
| Reproxalap Ophthalmic Solution (0.25% Novel… | Dry Eye | Phase 3 · NCT03879863 | Completed |
| Monthly ADX-2191 injection | Primary Vitreoretinal Lymphoma | Phase 3 · NCT07402876 | Recruiting |
| ICM ADX-2191 injection | Primary Vitreoretinal Lymphoma | Phase 3 · NCT07402876 | Recruiting |
| ADX-2191 | Proliferative Vitreoretinopathy | Phase 3 · NCT04136366 | Completed |
| Reproxalap | Non-infectious Anterior Uveitis | Phase 3 · NCT03131154 | Completed |
| ADX-102 1% Topical Dermal Cream (reproxalap) | Sjogren-Larsson Syndrome | Phase 3 · NCT03445650 | Completed |
| Active topical NS2 1% dermatologic cream | Sjögren-Larsson Syndrome | Phase 2 · NCT02402309 | Completed |
| NS2 Ophthalmic Drops (0.5%) | Allergic Conjunctivitis | Phase 2 · NCT02578914 | Completed |
| NS2 | Non-infectious Anterior Uveitis | Phase 2 · NCT02406209 | Completed |
| ADX-629 | Atopic Dermatitis | Phase 2 · NCT05717920 | Completed |
| ADX-102 Ophthalmic Solution (0.1%) | Dry Eye Syndromes | Phase 2 · NCT03162783 | Completed |
| ADX-102 Ophthalmic Lipid Solution (0.5%) | Dry Eye Syndromes | Phase 2 · NCT03162783 | Completed |
| ADX-102 Ophthalmic Drops (0.1%) | Conjunctivitis, Allergic | Phase 2 · NCT03012165 | Completed |
Also used in these trials (approved or third-party drugs, not ALDX's own candidates): Lifitegrast, Prednisolone Acetate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ALDX holds $41M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.4M/quarter from operations, an estimated runway of 28.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 10 · Low
Based on our current operating plan, and excluding any potential licensing and product revenue, we believe that our cash and cash equivalents as of September 30, 2026, will be sufficient to fund our currently projected operating expenses into 2029, including continued development and regulatory activities associated…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALDX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC 10% owner |
Insider | 5,875,851 | 9.74% | 2025-04-03 |
| Barclays PLC | Institution (13G, 5%+) | 3,310,587 | 5.49% | 2026-09-30 |
| Todd C Brady President and CEO, Director · +3.32M options |
Insider | 1,721,298 | 2.85% | 2026-06-03 |
| Richard Douglas Director · +5,227 options |
Insider | 395,000 | 0.65% | 2026-11-11 |
| Stephen Machatha Chief Development Officer · +202,427 options |
Insider | 221,799 | 0.37% | 2025-08-11 |
| Bruce Greenberg Interim Chief Financial Officer · +252,280 options |
Insider | 126,382 | 0.21% | 2024-08-12 |
| Michael Alfieri Principal Financial Officer |
Insider | 17,500 | 0.03% | 2026-11-11 |
| Darlene M Deptula-hicks Director · +9,756 options |
Insider | 7,500 | 0.01% | 2026-11-12 |
| Nancy Miller-Rich Director · +7,467 options |
Insider | 922 | 0.00% | 2021-05-03 |
Share count 60,356,541 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-03-17 | reproxalap | NDA | -19.4% | -70.7% | -47.3% |
| 2026-03-16 | Reproxalap | NDA | -22.5% | +2.6% | -56.1% |
| 2025-12-16 | Reproxalap | NDA | -20.5% | +33.1% | +38.9% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALDX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →